about
Lipoprotein(a) as a cardiovascular risk factor: current statusLipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptorConsensus statement on management of dyslipidemia in Indian subjects.Comparison of the effects of fibrates versus statins on plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of head-to-head randomized controlled trials.Lipoprotein(a) and cardiovascular disease in diabetic patientsLipoprotein (a): a Unique Independent Risk Factor for Coronary Artery Disease.Chemical composition-oriented receptor selectivity of L5, a naturally occurring atherogenic low-density lipoprotein.Correlation between serum levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) and atherogenic lipoproteins in patients with coronary artery diseasePlasma lipoprotein(a) levels in patients with slow coronary flow.Management of dyslipidemia in the elderly population.Vitamin D and cardiometabolic health: a review of the evidence.New directions in cardiovascular risk assessment: the role of secondary risk stratification markers.Dyslipidemias in the prevention of cardiovascular disease: risks and causality.Screening for and management of elevated Lp(a).Lipid Lowering Therapy and Circulating PCSK9 Concentration.Lipoprotein(a) and oxidized phospholipids in calcific aortic valve stenosis.Hyperlipoproteinaemia(a) - apheresis and emerging therapies.What is the role of alternative biomarkers for coronary heart disease?Evidence-based assessment of lipoprotein(a) as a risk biomarker for cardiovascular diseases - Some answers and still many questions.The DEFINE study: a bright future for CETP inhibitors?
P2860
Q24623225-1448633C-F48D-4F6C-AC63-F944F6ED54D9Q28258969-4CAFCBDA-9BBC-4631-BFB4-B37CC9AA7577Q34980772-B1536AF1-153F-468E-AE70-AFC5ED6844B7Q36268257-BDC8AA6F-72FD-463B-8E3A-C6F63FBD5EC5Q36369444-47650742-D0FA-41F7-A811-E13F82670132Q36515765-DCBF1E29-9318-4CB8-AB2C-D89D8792DB1CQ37276420-E7F4C35C-0569-4148-BC24-EF38F38B283CQ37278608-0E843889-EF27-4D99-86D4-E8693292A3C5Q37589605-0702009C-DA5C-41A4-9ABD-36E4C325A87BQ37802082-5073DDFE-1022-4662-8C04-EC80D0D938EEQ37813833-3B9FB900-EBC3-49DB-842F-48BBDA6B1B30Q38018722-E9171739-2535-43CE-9A8B-5DBAEF279E1DQ38042396-6ECEEB70-1F02-4CEB-9470-AB54D493DB56Q38140754-9C6E19A5-1C68-4D7F-9A2E-23839873D128Q38643197-6F19CEE3-1810-43CC-AAAB-94742FD742DCQ38839978-3591BFC6-89AA-40CF-8A80-7F7914382E3CQ38968510-28F6D10B-479E-4A65-8E4B-7734CB2B8A11Q39756989-10539C85-B46D-4A6B-8EF2-1802E4018068Q40757066-5EA344E7-81A4-404B-B632-D6E9ADA60401Q43439911-273ABDD5-1E66-479C-941C-61ED21A52F5A
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Lipoprotein a: where are we now?
@en
Lipoprotein a: where are we now?
@nl
type
label
Lipoprotein a: where are we now?
@en
Lipoprotein a: where are we now?
@nl
prefLabel
Lipoprotein a: where are we now?
@en
Lipoprotein a: where are we now?
@nl
P1476
Lipoprotein a: where are we now?
@en
P2093
Konstantinos Tziomalos
Vasilios G Athyros
P304
P356
10.1097/HCO.0B013E32832AC21A
P577
2009-07-01T00:00:00Z